Vita Life Sciences (VLS) AGM 2025 summary

Opening remarks and agenda

• The meeting was opened by the Chairman, confirming a quorum and introducing the board, management, and auditor, with instructions for online shareholder participation.

• The AGM was held at the company's new Mascot facility, highlighting its role in supporting future growth.

Financial performance review

• Achieved record revenue of AUD 79.5 million, up 8.3%, and pre-tax profit of AUD 12.6 million, up 1.5%.

• Total equity increased to AUD 52.3 million, net cash position at AUD 28.6 million, with no borrowings.

• Dividend payment of $0.10 per share declared, up 11.1%.

• Inventory levels increased to support anticipated demand, especially for China, with lead times normalizing to 3–6 months.

• Return on equity fell 20% due to higher working capital, but strong cash flow contributed to equity growth.

Board and executive committee updates

• Board reaffirmed focus on organic growth and prudent capital allocation, with no special dividend planned.

• Non-executive director remuneration to increase to AUD 300,000 from 2026, approved by proxy votes.

• Re-election of a director and adoption of the remuneration report passed with strong support.